Browse pathologies

breast cancer - adjuvant  14 studies   trastuzumab emtasine plus endocrine therapy everolimus abemaciclib plus endocrine therapy palbociclib plus endocrine therapy doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab docetaxel plus carboplatin with trastuzumab followed by trastuzumab lapatinib pertuzumab plus trastuzumab olaparib palbociclib trastuzumab emtansine pembrolizumab alone neratinib

breast cancer - HER2-positive  37 studies  

es-BC - HER2 negative - (neo)adjuvant (NA)  1 studies   pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide

es-BC - HER2 positive - (neo)adjuvant (NA)  6 studies   trastuzumab emtansine trastuzumab emtasine plus endocrine therapy lapatinib trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel

la/mBC - HER2 positive  30 studies  

la/mBC - HER2 positive - (neo)adjuvant (NA)  3 studies   lapatinib plus trastuzumab plus paclitaxel trastuzumab plus chemotherapy lapatinib plus paclitaxel

la/mBC - HER2 positive - 1st Line (L1)  7 studies   trastuzumab plus endocrine therapy pertuzumab plus trastuzumab pertuzumab plus trastuzumab plus docetaxel bevacizumab plus trastuzumab plus docetaxel trastuzumab

la/mBC - HER2 positive - 2nd Line (L2)  17 studies   abemaciclib plus trastuzumab lapatinib plus capecitabine afatinib plus vinorelbine neratinib plus capecitabine lapatinib plus trastuzumab tucatinib plus trastuzumab plus capecitabine inetetamab plus vinorelbine margetuximab plus chemotherapy trastuzumab emtansine trastuzumab deruxtecan abemaciclib plus trastuzumab plus fulvestrant neratinib lapatinib

breast cancer - HR positive  44 studies  

es-BC - HR positive - (neo)adjuvant (NA)  2 studies   trastuzumab emtansine trastuzumab emtasine plus endocrine therapy

es-BC - HR-positive - 1st line (L1)  1 studies   taselisib plus letrozole

la/mBC - HR positive  41 studies  

la/mBC - HR positive - (neo)adjuvant (NA)  3 studies  

la/mBC - HR positive - NA - PIK3CA mutant 

la/mBC - HR-positive - 1st line (L1)  14 studies  

la/mBC - HR positive - L1 - PIK3CA mutant  1 studies   ipatasertib plus paclitaxel

la/mBC - HR-positive - 2nd line (L2)  22 studies  

la/mBC - HR positive - L2 - all population  1 studies   buparlisib plus fulvestrant

la/mBC - HR positive - L2 - PIK3CA mutant  1 studies   buparlisib plus fulvestrant

breast cancer - triple negative  29 studies  

es-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)  6 studies  

es-BC - TNBC - NA - all population  5 studies   olaparib atezolizumab plus carboplatin plus nab-paclitaxel atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide pembrolizumab alone durvalumab alone

es-BC - TNBC - NA - PDL1 positive  1 studies   atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide

es-BC - Triple negatif (TNBC) - 1st line (L1) 

mBC - Triple negative (TNBC) - (neo)adjuvant (NA) 

mBC - Triple negative (TNBC) - 1st Line (L1)  13 studies  

mBC - TNBC - L1 - all population  8 studies   paclitaxel plus carboplatin veliparib plus paclitaxel plus carboplatin ipatasertib plus paclitaxel capivasertib plus paclitaxel pembrolizumab plus SoC atezolizumab plus paclitaxel atezolizumab plus nab-paclitaxel

mBC - TNBC - L1 - PDL1 positive  4 studies   atezolizumab plus paclitaxel pembrolizumab plus SoC atezolizumab plus nab-paclitaxel

mBC-Triple negative (TNBC) - 2nd Line (L2)  10 studies  

mBC - TNBC - L2 - all population  5 studies   pembrolizumab alone olaparib

mBC - TNBC - L2 - PDL1 positive  2 studies   pembrolizumab alone

metastatic/advanced - breast cancer (mBC)  1 studies   trastuzumab deruxtecan